Veru

$13.72
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.46 (-3.22%) Today
-$0.10 (-0.72%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell Veru and other stocks, options, and ETFs commission-free!

About VERU

Veru Inc. Common Stock, also called Veru, is an oncology biopharmaceutical company engaged in developing novel medicines for the management of prostate cancer and breast cancer. Its prostate cancer drug candidates include: VERU-111, an oral alpha and beta tubulin inhibitor, which is in a Phase 2 clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a novel, proprietary, GnRH antagonist peptide drug formulation designed to address the current limitations of commercially available androgen deprivation therapies (ADT) for advanced prostate cancer; and Zuclomiphene Citrate, an oral nonsteroidal estrogen receptor agonist being developed to treat hot flashes, a common side effect caused by ADT. The firm’s breast cancer drug candidates include: Enobosarm, an oral, new chemical entity, selective androgen receptor agonist that targets the androgen receptor in AR+/ER+/HER2-hormone sensitive metastatic breast cancer without unwanted virilizing side effects; and VERU 111 for triple negative metastatic breast cancer that has become resistant to taxane IV chemotherapy. It is also advancing the new drug formulation TADFYN, tadalafil and finasteride combination capsules for the treatment of men with lower urinary tract symptoms. The company’s sexual health business’ commercial product is the FC2 Female Condom/FC2 Internal Condom, an FDA-approved product for dual protection against unintended pregnancy and the transmission of sexually transmitted infections which is sold commercially and in the public health sector both in the U.S. and globally. Veru was founded by William R. Gargiulo, Jr. and O. B. Parrish in 1996 and is headquartered in Miami, FL. The listed name for VERU is Veru Inc. Common Stock.

CEO
Mitchell Shuster Steiner
Employees
339
Headquarters
Miami, Florida
Founded
1996
Market Cap
1.15B
Price-Earnings Ratio
69.10K
Dividend Yield
—
Average Volume
3.87M
High Today
$14.75
Low Today
$13.42
Open Price
$14.33
Volume
1.64M
52 Week High
$24.57
52 Week Low
$2.30

VERU Earnings

-$0.06
-$0.03
$0.00
$0.03
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Q2 FY21
Estimated
— per share
Actual
Expected May 12, Pre-Market

You May Also Like

PRPL
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure